Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Romosozumab · Evenity, AMG-785

Monoclonal antibody · Antagonist of sclerostin (SOST) · developed by Amgen

Approved FDA, Apr 2019
AMGN Developer
1 Registered trials

What is Romosozumab?

Romosozumab is a humanized IgG2 monoclonal antibody that inhibits sclerostin, a negative regulator of bone formation. It stimulates osteoblastic activity, increasing bone formation and decreasing bone resorption to improve bone mass and structure.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Evenity, AMG-785, CDP-7851
Drug type
Monoclonal antibody
Targets
sclerostin (SOST)
Mechanism
Antagonist of sclerostin (SOST)
Pathways
Wnt signaling, osteoblast development and function
Therapy area
Endocrine
Developer
Amgen Inc (AMGN)
FDA status
Approved as Evenity (April 9, 2019), BLA761062 · FDA label
UNII
3VHF2ZD92J

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 16, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07811999 Phase 1 Healthy Participants Not yet recruiting AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Participants

More from Amgen

Apremilast FDA approved Blinatumomab FDA approved Carfilzomib FDA approved Denosumab FDA approved Erenumab FDA approved Evolocumab FDA approved Pegloticase FDA approved Prednisone FDA approved Romiplostim FDA approved Sotorasib FDA approved Tarlatamab FDA approved ABP 692 Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AMGN page.

Follow AMGN, the company behind Romosozumab

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.